Loading...
•
Sep 30, 2024
Mural Oncology Q3 2024 Earnings Report
Announced third quarter 2024 financial results and provided update on pipeline progress.
Key Takeaways
Mural Oncology reported its third quarter 2024 financial results, highlighting the company's ongoing progress in late-stage trials of nemvaleukin alfa and the expected nomination of candidates for IL-18 and IL-12 programs. The company remains on track with its clinical trials and reiterates its guidance on projected cash runway into Q4 2025.
Late-stage trials of nemvaleukin alfa remain on track, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma.
Candidate nominations for IL-18 and IL-12 programs are expected in Q4 2024, with an IND submission for Mural’s IL-18 program planned for Q4 2025.
Mural reaffirms guidance on projected cash runway into Q4 2025.
Enrollment completed in ARTISTRY-7 and ARTISTRY-6 trials.
Forward Guidance
Mural Oncology reaffirms guidance that its cash, cash equivalents, and marketable securities as of September 30, 2024 are expected to fund its operations into the fourth quarter of 2025. Management forecasts lower operating expenses in 2025 versus 2024 due to the timing of clinical trial expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...